Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Angiodynamics (ANGO) Operating Expenses (2016 - 2026)

Angiodynamics' Operating Expenses history spans 17 years, with the latest figure at $54.4 million for Q1 2026.

  • For Q1 2026, Operating Expenses rose 11.47% year-over-year to $54.4 million; the TTM value through Feb 2026 reached $205.9 million, up 1.6%, while the annual FY2025 figure was $197.7 million, 50.79% down from the prior year.
  • Operating Expenses reached $54.4 million in Q1 2026 per ANGO's latest filing, up from $50.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $242.4 million in Q1 2024 to a low of $43.9 million in Q1 2022.
  • Average Operating Expenses over 5 years is $63.5 million, with a median of $52.9 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: soared 390.4% in 2024, then plummeted 79.86% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $53.2 million in 2022, then rose by 0.36% to $53.4 million in 2023, then fell by 4.46% to $51.0 million in 2024, then dropped by 0.18% to $50.9 million in 2025, then increased by 6.92% to $54.4 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Operating Expenses are $54.4 million (Q1 2026), $50.9 million (Q4 2025), and $52.5 million (Q3 2025).